Premier Fund Managers’s Castle Biosciences CSTL Stock Holding History

Premier Fund Managers’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14,783	Closed	-$312K	–	192
2024 Q2	$312K	Hold	14,783	–	–	0.01%	177
2024 Q1	$314K	Buy	+14,783	New	+$322K	0.01%	186
2023 Q1	–	Sell	-38,502	Closed	-$892K	–	227
2022 Q4	$892K	Sell	38,502 -13,780	-26%	-$319K	0.03%	178
2022 Q3	$1.33M	Hold	52,282	–	–	0.1%	98
2022 Q2	$1.2M	Hold	52,282	–	–	0.05%	162
2022 Q1	$2.3M	Hold	52,282	–	–	0.08%	153
2021 Q4	$2.29M	Sell	52,282 -29,772	-36%	-$1.56M	0.07%	148
2021 Q3	$5.32M	Hold	82,054	–	–	0.17%	131
2021 Q2	$6.12M	Sell	82,054 -26,387	-24%	-$1.74M	0.21%	118
2021 Q1	$6.76M	Hold	108,441	–	–	0.26%	100
2020 Q4	$7.46M	Buy	108,441 +35,996	+50%	+$1.95M	0.32%	72
2020 Q3	$3.66M	Buy	+72,445	New	+$3.22M	0.21%	111

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Premier Fund Managers's CSTL Position: Q3 2024 in Review

Premier Fund Managers sold out of Castle Biosciences (CSTL) in Q3 2024, closing a stake of 14,783 shares — an estimated $312K sold.

Premier Fund Managers first reported a position in CSTL in Q3 2020 and held it in 12 quarters. The position peaked at $7.46M in Q4 2020. 185 funds tracked by Wall St. Rank hold CSTL as of Q3 2024.

Premier Fund Managers reported no remaining Castle Biosciences position as of Q3 2024 after selling out during the quarter.
Premier Fund Managers sold 14,783 Castle Biosciences shares in Q3 2024, an estimated $312K.
Premier Fund Managers first reported a position in Castle Biosciences in Q3 2020 and held it in 12 quarters.
Premier Fund Managers's Castle Biosciences position peaked at $7.46M in Q4 2020.
185 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2024.

Based on Premier Fund Managers's 13F filing for Q3 2024, filed 8 Nov 2024.